Table 5 Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt and co-workers [[31]]
Mainz cohort (n=158) | Rotterdam cohort (n=178) | Transbig cohort (n=186) | Combined cohorts (n=522) | ||
|---|---|---|---|---|---|
A. Univariate analysis | |||||
ER+/HER2- | |||||
AURKA | P-value | 0.011 | <0.001 | <0.001 | <0.001 |
HR | 1.786 | 2.916 | 2.174 | 2.100 | |
95%-CI | 1.144-2.787 | 2.022-4.206 | 1.491-3.171 | 1.700-2.594 | |
Mainz cohort ( n = 23 ) | Rotterdam cohort ( n = 58 ) | Transbig cohort ( n = 59 ) | Combined cohorts ( n = 140 ) | ||
ER-/HER2- | |||||
AURKA | P-value | 0.497 | 0.808 | 0.924 | 0.993 |
HR | 1.534 | 1.103 | 0.967 | 1.002 | |
95%-CI | 0.446-5.282 | 0.498-2.443 | 0.483-1.934 | 0.637-1.577 | |
Mainz cohort ( n = 19 ) | Rotterdam cohort (n=50=) | Transbig cohort (n=35) | Combined cohorts (n=104) | ||
HER2+ | |||||
AURKA | P-value | 0.298 | 0.840 | 0.100 | 0.402 |
HR | 2.303 | 1.088 | 0.439 | 0.785 | |
95%-CI | 0.478-11.091 | 0.481-2.461 | 0.165-1.171 | 0.446-1.382 | |